The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study

Retina

Volumn 29, Issue 1, 2009, Pages 20-26

  Velez Montoya, Raul ^a,d   Fromow Guerra, Jans ^a   Burgos, Octavio ^a   Landers III, Maurice B ^b   Morales Catón, Virgilio ^a   Quiroz Mercado, Hugo ^c  

^a Asociacion para Evitar la Ceguera en Mexico IAP   (Mexico)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Vicente García Torres 46   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DRUG EFFECT; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; RETINAL THICKNESS; VISION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; DIABETIC RETINOPATHY; DRUG ANTAGONISM; HEMISPHERIC DOMINANCE; INJECTION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RETINA; RETINA MACULA EDEMA; TREATMENT OUTCOME; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; FUNCTIONAL LATERALITY; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 61549094645     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318186c64e     Document Type: Article

References (22)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219: 983-985.
2. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevaci-zumab (Avastin) therapy for persistent diffuse diabetic macu-lar edema. Retina 2006;26:999-1005.
3. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
4. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
5. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
6. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevaci-zumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
7. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
8. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevaci-zumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606.
9. Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, et al. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol 2006;124: 1701-1707.
10. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998;105:360-370.
11. Frank RN, Schulz L, Abe K, Iezzi R. Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology 2004;111:221-227.
12. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005;140:200-206.
13. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999;127:688-693.
14. Otani T, Kishi S. Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema. Ophthalmology 2007;114:104-107.
15. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718.
16. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
17. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharma-cokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
18. Bresnick GH. The Early Treatment Diabetic Retinopathy Study: an update. J Diabet Complications 1988;2:105-108.
19. Pelzek C, Lim JI. Diabetic macular edema: review and update. Ophthalmol Clin North Am 2002;15:555-563.
20. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19.
21. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatra-man AS. Systemic bevacizumab (Avastin) therapy for neovas-cular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
22. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814 -2823.